25 completed. 25 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 25 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Hyperphosphatemia: new trials by email Literature Review of Hyperphosphatemia trials Research Report on Hyperphosphatemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients VS-505, Sevelamer Carbonate - Hyperphosphatemia | Phase 2 | Completed | Shanghai Alebund Pharmaceuticals Limited | 158 | 2020-10-13 | 2022-10-18 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebp - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 47 | 2019-04-29 | 2024-03-07 |
| Dose-finding Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebo - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 207 | 2019-04-15 | 2024-03-07 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD KHK7791 - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 67 | 2018-12-27 | 2024-03-07 |
| Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease PT20, Placebo - Hyperphosphataemia | Phase 2 | Completed | Phosphate Therapeutics | 153 | 2014-05-07 | 2018-01-16 |
| Dose Finding Study to Treat High Phosphate Levels in the Blood. AZD1722, Placebo - Hyperphosphatemia | Phase 2 | Completed | Ardelyx | 162 | 2014-03-01 | 2020-09-14 |
| Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Osvaren Granules, Osvaren film-coated tablets - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Fresenius Medical Care Deutschland GmbH | 61 | 2014-01-01 | 2015-06-10 |
| A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis Lanthanum Carbonate, Calcium Carbonate - Chronic Kidney Disease, Hyperphosphatemia | Phase 2 | Completed | Shire | 63 | 2013-02-15 | 2021-06-10 |
| An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease Placebo, Sevelamer carbonate - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | Genzyme, a Sanofi Company | 101 | 2012-05-01 | 2016-07-25 |
| PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia PA21, Placebo - Chronic Kidney Disease Requiring Hemodialysis | Phase 2 | Completed | Kissei Pharmaceutical Co., Ltd. | 183 | 2012-01-11 | 2018-08-23 |
| Nicotinamide in Hemodialysis Patients With Hyperphosphatemia Nicotinamide - Chronic Kidney Disease, Hemodialysis | Phase 2 | Completed | Medice Arzneimittel Pütter GmbH & Co KG | 252 | 2010-08-01 | 2012-01-18 |
| A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia HS219, Placebo - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | KDL Inc. | 68 | 2009-12-01 | 2015-09-14 |
| Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis Placebo, Genz-644470, Sevelamer carbonate - Kidney Failure, Chronic | Phase 2 | Completed | Genzyme, a Sanofi Company | 349 | 2009-02-01 | 2015-05-01 |
| Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis SBR759, Sevelamer HCl - Chronic Kidney Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 203 | 2008-08-01 | 2016-09-23 |
| Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis SBR759, Sevelamer HCl - Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy | Phase 2 | Completed | Novartis Pharmaceuticals | 321 | 2008-07-01 | 2020-12-19 |
| A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) ferric citrate - Hyperphosphatemia, End-stage Renal Disease | Phase 2 | Completed | Keryx Biopharmaceuticals | 55 | 2008-03-01 | 2017-04-04 |
| Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder - Hyperphosphatemia, Kidney Disease | Phase 2 | Completed | University of Illinois at Chicago | 11 | 2008-01-01 | 2020-11-03 |
| A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis ASP1585, Placebo, Sevelamer hydrochloride - Hyperphosphatemia, Chronic Kidney Disease | Phase 2 | Completed | Astellas Pharma Inc | 156 | 2007-10-01 | 2011-03-22 |
Showing 20 of 25. Sign in to see all of them.
Renal Insufficiency, Chronic (10) · Kidney Failure, Chronic (6) · Bronchiolitis Obliterans Syndrome (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Kidney Diseases (1) · Renal Insufficiency (1)
Metabolic Diseases (25) · Nutritional and Metabolic Diseases (25) · Phosphorus Metabolism Disorders (25) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Male Urogenital Diseases (16) · Urogenital Diseases (16) · Urologic Diseases (16) · Chronic Disease (15) · Disease Attributes (15) · Kidney Diseases (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Renal Insufficiency (14) · Renal Insufficiency, Chronic (5)
Sevelamer (9) · lanthanum carbonate (3) · tenapanor (3) · Calcium Carbonate (2) · Niacinamide (2) · SBR 759 (2) · ferric citrate (2) · iron-magnesium hydroxycarbonate (2) · Iron (1) · calcium acetate (1) · sucroferric oxyhydroxide (1)
Kyowa Kirin Co., Ltd. (3) · Ardelyx (2) · Bayer (2) · Genzyme, a Sanofi Company (2) · Ineos Healthcare Limited (2) · Novartis Pharmaceuticals (2) · Alebund Pharmaceuticals (1) · Astellas Pharma Inc (1) · Fresenius Medical Care Deutschland GmbH (1) · KDL Inc. (1) · Keryx Biopharmaceuticals (1) · Kissei Pharmaceutical Co., Ltd. (1) · Medice Arzneimittel Pütter GmbH & Co KG (1) · Phosphate Therapeutics (1) · Shanghai Alebund Pharmaceuticals Limited (1)
Japan (9) · United States (9) · Germany (5) · United Kingdom (4) · Poland (3) · China (2) · France (2) · Puerto Rico (2) · Argentina (1) · Australia (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · Finland (1)
Alan H Lau, Pharm.D. (1) · Daniel O Young, MD (1) · David P Rosenbaum, PhD (1) · Geoff Block, MD (1) · Geoffrey A Block, MD (1) · Julia B Lewis, MD (1) · Li Wang, MD (1) · Maarten Taal, MBChB MD FRCP (1) · Masafumi Fukagawa, MD, PhD (1) · Simon Roe, MB ChB (1)
PMID 40576086, PMID 21854503, PMID 38323855, PMID 19776051, PMID 21426511, PMID 24968790, PMID 24975892, PMID 29617976, PMID 32651955, PMID 33766811, PMID 35236302, PMID 38453435
2009 (1)